Detalles de la búsqueda
1.
A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib.
Mol Cancer
; 21(1): 66, 2022 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35246156
2.
Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib.
Mol Cancer
; 21(1): 134, 2022 Jun 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35739513
3.
[Research Progress of Oral BCL-2 Inhibitor Venetoclax in the Treatment of Non-Hodgkin's Lymphoma --Review].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 30(5): 1622-1626, 2022 Oct.
Artículo
en Zh
| MEDLINE | ID: mdl-36208277
4.
[Efficacy and Safety of Cladribine-based Intensified Conditioning Regimen in Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 30(1): 65-71, 2022 Feb.
Artículo
en Zh
| MEDLINE | ID: mdl-35123605
5.
Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway.
Int Immunopharmacol
; 104: 108497, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34999394
Resultados
1 -
5
de 5
1
Próxima >
>>